Form 4: Vivani Medical CEO Adam Mendelsohn Reports Stock Option and RSU Grants
SEC Form 4 Filing
Adam Mendelsohn, CEO of Vivani Medical, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.
Summary
- Adam Mendelsohn, the CEO of Vivani Medical, filed a Form 4 with the SEC.
- The filing reports the grant of stock options and restricted stock units (RSUs).
- Mendelsohn was granted options for 200,000 shares of common stock with an exercise price of $1.81, vesting over 4 years.
- He also received 100,000 performance-based RSUs that vest in three stages based on the stock price reaching $3.15 for three consecutive trading days and continued service.
- A Limited Power of Attorney was executed on December 6, 2023, appointing Adam Mendelsohn, Judy Wong, and Brigid Makes to act on behalf of the undersigned for SEC filings.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as the equity grants align management incentives with shareholder value creation. The performance-based vesting adds a further positive element.
Positives
- The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders.
- The performance-based vesting of the RSUs incentivizes the CEO to drive up the stock price.
Risks
- The RSUs will expire if the stock price does not reach $3.15 within four years from the grant date.
- The vesting of both the options and RSUs is contingent on the CEO's continued service.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the options and RSUs.
Industry Context
Granting stock options and RSUs to executives is a common practice in the pharmaceutical and biotech industries to incentivize performance and align management's interests with shareholders.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation practices in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely use equity-based compensation to attract and retain talent.
- The vesting schedules and performance-based conditions are also typical, designed to incentivize long-term value creation.
Stakeholder Impact
- Shareholders may view the equity grants positively as they incentivize management to increase the company's value.
- Employees may be motivated by the potential for increased company value and stock price appreciation.
Key Dates
| Date | Description |
|---|---|
| 2023-12-06 | Date of execution for the Limited Power of Attorney. |
| 2024-05-10 | Date of the earliest transaction reported (grant of stock options and RSUs). |
| 2034-05-09 | Expiration date of the stock options. |
| 2024-05-14 | Date of the SEC filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.